

ersonal use only

# MICRO-X

ACN 153 273 735 / ASX: MX1

## CEO PRESENTATION

**CLEAR VISION**  
**FOCUSED EXECUTION**

AGM - 19 November 2021

Peter Rowland  
Managing Director & CEO



The video played at the meeting can be viewed on the Company's website

# KEY ACHIEVEMENTS FOR FY2021

MICRO-X

Micro-X laid out the infrastructure for future growth across all four products



**\$3.6m of sales** + establishment of **multiple distributorships, non-exclusive paths** to market  
- **Mobile DR range**



**'Argus' bomb detection on time and budget - strong police and military interest** for 2022 launch  
- **X-ray camera**



**\$8m non-dilutive funding** with ASA under **MRFF programme**  
- **Stroke CT scanner**



**Veterinary market launch** and first sale into Australia  
- **Mobile DR range**



**Rover Mark II high power generator & tube** tested with 4 times the output and same size  
- **Mobile DR range**



Up to **US\$4.0m non-dilutive funding** from **US Department of Homeland Security**  
- **Airport Security Checkpoints**



**Micro-X Rover – US 510(k) and on Australian ARTG** - higher margin and Micro-X branded  
- **Mobile DR range**



**Bolstered US sales, marketing and engineering activities** with **Seattle office**



Successful **\$34m capital raising** – now **debt free**

ersonal use only

# OUR STRATEGY

How we Plan to Monetise Our 'First Mover' Advantage


MICRO-X

ersonal use only

**OUR GOAL**

**Four production lines**

- common technology platforms
- global sales volumes
- no competitive alternative
- high-margin
- operating within five years



# ONE COMPANY – FOUR BUSINESSES

Each unique product drives a new market-focused Business Unit

MICRO-X



## Mobile DR

First Sales  
**2018**

Addressable Market  
**US\$500m pa\***

\* Pre COVID-19 levels , Omdia Market Report



## Cameras

First Sales  
**2022**

Addressable Market  
**US\$1.8b\***

\* Estimate based on published numbers of EOD Teams world-wide, potential volume & price



## Checkpoints

First Sales  
**2024**

Addressable Market  
**USA: US\$8b\***  
**RoW: US\$16b\***

\* Estimate based on published TSA data, potential volume & price



## CT

First Sales  
**2026**

Addressable Market  
**US\$5b\***

\* Estimate based on published numbers of Ambulances in USA & EUR, potential volume & price

Note: Dates are estimates and may vary

ersonal use only

ersonal use only

MICRO-X

MOBILE DR  
BUSINESS UNIT

---

Driving Point-of-Care  
Imaging Further

---



# MOBILE DR – CONTROLLING OUR DESTINY

Building Commercial Capability – New Markets and Sales Channels

MICRO-X

- ✘ **Strategy** – lead by Charlie Hicks (30yr Radiology Industry expert)
    - **Direct Sales executives** – deep relationships in radiology and equipment sales
    - **Independent Distributors and Dealerships** - in all key markets – non-exclusive
    - **Major OEM Partners** – global radiology companies - non-exclusive
  - ✘ **Installed Base** – over 250 units in service in 30 countries
  - ✘ **Sales** - \$3.6m for FY21 plus \$1.3m ADF contract
  - ✘ **Customer Demand growing across all key markets**
    - **USA** – Seattle office building and supporting opportunities
    - **EMEA** – Arab Health 2021 with new Distributor - **UK support base**
    - **Australia / Oceania** - ARTG listed in 2021 - direct sales growing
- ✘ **November 29 - MAJOR COMMERCIAL LAUNCH at RSNA Conference**



ersonal use only

# MOBILE DR - MAJOR LAUNCH & REBRANDING

RSNA – Largest Global Radiology Conference – 29 November 2021

MICRO-X



Showcasing **Micro-X** branding, **Gen 2 product range** & **Tubes for Life** warranty

ersonal use only



# MOBILE DR – EXTENDED PORTFOLIO

Point-of-Care Imaging - light weight and ultra-mobile for all applications

MICRO-X

**New Go to Market Strategy with updated branding & materials**  
- greater customer focus and **higher product margins**

- ✘ **Micro-X | Pico** - Acute hospitals & temporary facilities
- ✘ **Micro-X | Neo** - Specialist paediatric & neo-natal ICU x-ray
- ✘ **Micro-X | Rover** – Rugged version for range of non-hospital applications
  - **Military** deployed hospitals and humanitarian aid
  - **In-home** for Door-to-door service
  - **Veterinary** for Small-animal hospitals
- ✘ **OEM** – Carestream DRX-Revolution Nano



ersonal use only

# MOBILE DR – FEATURES DRIVING SALES

Product features underpin strong differentiation over competition

MICRO-X

## Key selling features today

- ✘ Small size and weight gives ultra-mobility
- ✘ Extreme Reliability – ‘Tubes for Life’
- ✘ Workflow deigned by Radiographers
- ✘ COVID – Rapid IC procedure, high intensity workflow
- ✘ Premium tier performance at mid-tier pricing

## Future applications delivering greater customer value

- ✘ Fluoroscopy
- ✘ Dual Energy imaging
- ✘ Bone Mineral Density Measurement



ersonal use only

ersonal use only

MICRO-X

X - R A Y C A M E R A  
B U S I N E S S U N I T

---

S a v i n g L i v e s b y  
S e e i n g D i f f e r e n t l y

---



# X-RAY CAMERA-REVOLUTIONISING BOMB DISPOSAL MICRO-X

Saving lives in the world's most dangerous workplace



- ✘ **Global Problem** – all IED Assessment with conventional x-ray requires placing a **separate imaging detector**
- ✘ Need to be 'Over the Target' with **huge risk to human life**

ersonal use only

# X-RAY CAMERA – ‘ARGUS’

MICRO-X

Demonstrated capability driving strong customer interest

## Key features are unparalleled

- ✘ World's only bomb detector **without a separate imaging detector**
- ✘ Self-contained 'camera' carried by EOD robot for remote viewing
- ✘ High resolution image allows diagnosis to component level
- ✘ Small size – 15kg - integrates with all common robots
- ✘ Suits military and counter terrorism / police market




ersonal use only

# X-RAY CAMERA – COMMERCIAL EXECUTION

MICRO-X

2022 will be a pivotal year with planned first sales



\* Dates are estimates

ersonal use only

# X-RAY CAMERA – PREPARING FOR 2022 LAUNCH MICRO-X

Pre-launch marketing to building awareness and sales pipeline


## Target addressable market is \$1.8B

- ✦ Police (urban counter-terrorism), Military (counter-IED), Border Forces (contraband)
  - Globally there are **5,500 counter-IED units\***
  - **698 Police bomb squads** in North America\*
  - **US Defense** has 6,200 EOD personnel and **operates over 2,000 EOD robots\***

## Micro-X Dedicated sales team engaging with customers

- ✦ Ex–military EOD sales staff leading marketing in USA & Australia
- ✦ Exhibited in major Defence/Security expositions
  - London
  - Washington DC
- ✦ Formal responses provided to RFIs in UK and Australia

\*Source: Published CBRN Industry Data



# X-RAY CAMERA - FUTURE DEVELOPMENT

MICRO-X

Mine clearance and disposal for the ADF



*Concept of Argus performing Route Clearance activities*



*Argus detecting a buried mine*

ersonal use only



ersonal use only

MICRO-X

CHECKPOINTS  
BUSINESS UNIT

---

A Better Experience  
for Travellers

---



# CHECKPOINTS – TRANSFORMING TRAVEL

MICRO-X

Self service checkpoints – Speed and safety for future travellers

## Customer driven concept to improve travel experience

- ✘ Passenger self-directed screening – **integrates** with passport scanning, photometric ID, body scan, baggage CT
- ✘ Automation will improve experience - **faster**
- ✘ Automated and enhanced threat detection - **safer**
- ✘ Individual screening portals – **privacy**
- ✘ Less interaction with security staff – **efficient** & **COVID safe**


## Market opportunity is US\$24B in airports alone

- ✘ US\$8B in US airports
- ✘ TSA annual Manpower cost of checkpoints is \$4B
- ✘ Scalable for **all transport, government building, stadiums**



# CHECKPOINT – CORE TECHNOLOGY ADVANTAGES MICRO-X

Enabled by Cold Cathode X-ray – proven by UK Future Aviation Security contract



## Technology enabler

- ✦ Micro-X CNT technology enables miniaturised high-resolution dual-energy CT scanners – size and speed
- ✦ **Successful UK concept demonstration** – Heathrow Airport, 2018

## US government contracts funding development

- ✦ DHS fully funding development – **prototype scanner for testing by late 2022**

## Future applications using AI and machine learning

- ✦ Develop machine learning capability in-house as a part of the DHS funded development

Source: Micro-X

# CHECKPOINTS – COMMERCIAL BY 2023

Funded by the only two Contracts with US Dept. of Homeland Security

MICRO-X

## Miniaturised CT – Baggage scanner



- ✘ Miniaturised x-ray computed tomography – three -dimensional imaging of carry on luggage – enables implementation of automated detection of threats.

- ✘ Modular baggage scanner fits into both current checkpoint and future self-service checkpoint

### Compelling value proposition for DHS

- ✘ TSA operates 2,200 x-ray lanes across 440 airports in the United States\*
- ✘ TSA manpower cost is \$4B annually\*
- ✘ Each current x-ray lane can be replaced by 5 Portals > 300 passengers an hour
- ✘ Each current x-ray lane has the same footprint as 8 Portals

## Full Self-Service Portal



- ✘ Portal integrates document scanning, photometric ID, body scan, baggage CT
- ✘ Passenger self-directed screening to increase throughput, improve security, provide greater privacy, and enhance total experience.

\*Source: TSA Annual Report

ersonal use only

# CHECKPOINT – STRATEGY

Micro-X is taking Leadership Role, Prime Contracting with our Collaborators

## MICRO-X


### MICRO-X

Developing Transformative  
Core Technology



### MICRO-X

Leading a Global  
Team of Innovators



Real-time Mm-  
wave on-person



Automation & ID  
Verification



Monash University  
Human Factors



System Integration



Video Analytics

### MICRO-X

Engaging with Regulators  
and Customers



Homeland  
Security  
Science and Technology



Transportation  
Security  
Administration



Department  
for Transport



### MICRO-X

Actively Participating  
Industry Work Shops:



ersonal use only

ersonal use only

MICRO-X

CT  
BUSINESS UNIT

---

CT so Small it can Fly

---



# CT - A NEW STANDARD OF CARE FOR STROKE

MICRO-X

Taking stroke diagnosis from the hospital to the ambulance

## Saving lives for millions of stroke victims – the Golden Hour

- ✘ Nearly 2 million brain cells die per minute during an ischemic stroke
- ✘ Three out of four strokes are clots – **diagnostic standard is using CT to rule out any bleeding** - clot-busting drugs can then be administered
- ✘ Early diagnosis to commence treatment in the ambulance – saves lives
- ✘ Growing mobile stroke units hampered by limits of current technology – conventional CT is too bulky, too heavy, too expensive, too unreliable



## Market opportunity for mobile stroke diagnosis is US\$5B

- ✘ 48,000 Road Ambulances in North America and 60,000 in Europe
- ✘ Air ambulances and other mobile healthcare applications
- ✘ Goal to provide in-ambulance stroke diagnosis & treatment – **before hospital**






Source: Melbourne Brain Centre & published data

# CT – STROKE DIAGNOSIS USING MICRO-X CNT

MICRO-X

Enabling highly mobile and miniature X-Ray imaging for stroke diagnosis



## Current technology – large and heavy

- ✘ A conventional CT gantry spins at 200rpm
- ✘ Major size, weight and cost challenges
- ✘ Appropriate for hospital use but **not an ambulance**

## CNT delivers perfect solution – small and mobile

- ✘ Mobile CT with **29 mini X-ray tubes** and **no moving parts**
- ✘ Multiple cone-beam x-rays in sequence
- ✘ Dual energy key to achieving blood/brain contrast
- ✘ Curved imaging detector - **the first of its kind** - Fujifilm

ersonal use only



# CT – COMMERCIAL PRODUCT IN 4 YEARS

MICRO-X

A\$8m Australian Government MRFF programme – Stroke Golden Hour

## \$8m funding from Australian Stroke Alliance

- ✘ Robust CT imager with no moving parts
  - small enough and affordable to be fitted to every ambulance (land & air)
- ✘ Micro-X CT Scanner expects to **image smaller than 1mm bleeds** – ‘Standard of Care’ CT for MSU diagnosis can see 2mm bleeds
- ✘ **Micro-X CT is not changing current mobile diagnostic criteria**
  - proven in existing mobile units
- ✘ **Micro-X CT enables widespread proliferation of stroke care in every ambulance**
  - being smaller and cheaper – access for rural and remote locations

## Pathway to Regulatory Approval in 4 years

- ✘ First cadaver and human imaging trials in 2023 / 2024
- ✘ Regulatory submissions in 2024 / 2025

## Leveraging Partners for Excellence



# SUMMARY - FOUR DEDICATED BUSINESSES

MICRO-X

Focused resourcing and accountability to maximise growth

## Mobile DR - Healthcare

- **Medical, Military and Veterinary**
- **Customers** – hospitals, military, vets
- **US FDA, CE mark and ARTG listed**
- **\$3.6M of Mobile DR sales in FY2021** with growing sales capabilities

## Checkpoints - Security

- **Total addressable market of \$24.0B**
- **Customers** – Airports, transport, governments
- **US DHS funding development of commercial prototypes for up to US\$4m**



## X-Ray Camera - Security

- **Total addressable market of \$1.8B**
- **Customers** - defence and civilian bomb disposal teams
- **Live demonstrations and first sales commencing in 2022**

## CT - Healthcare

- **Total addressable market of US\$5.0B**
- **Customers** – ambulance, hospitals and radiology networks
- **MRFF funding development of commercial prototype for \$8m**

# IMPORTANT NOTICE



## SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

## FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

## NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

## UNITED STATES

**The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933**, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

## OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

ACN 153 273 735 / ASX: MX1

ersonal use only

MICRO-X

THANK YOU

